Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
BOCA RATON, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the successful launch of its new “Fair Deal Agreement” for the SRT-100 Vision™ (IG-SRT) at the AAD 2024 Annual Meeting, held March 8-12 in San Diego. This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event.
- This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event.
- Sensus manufactures and sells the only proven, FDA-cleared IG-SRT system and holds a patent for SRT combined with ultrasound, which is deeper and more effective.
- “The AAD Annual Meeting was the ideal forum to launch our new Fair Deal Agreement program, and the response among conference attendees exceeded our most optimistic expectations.
- This technology is ideal for better managing dermatology clinical practice, and is a Sensus Healthcare exclusive.